| |
Preclinical and In Vitro Resistance Profile of Potent Nucleotide Polymerase Inhibitors of HCV: ALS-2200 and its Single Diastereomer, VX-135
|
| |
| |
Reported by Jules Levin
8th International Workshop on Hepatitis C: Resistance & New Compounds, June 27-28, 2013, Boston, MA, USA
H. Tan1, A. Jekle1, H. Kang1, C. Moy1, J. Deval1, Z. Jin1, M. Jiang2, A. Ardzinski2, N. Dyatkina1, S.M. Chanda1, T.L. Kieffer2, L.M. Blatt1, L. Beigelman1, D.B. Smith1, J.A. Symons1
1. Alios BioPharma, South San Francisco, CA, United States; 2. Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States
|
|
| |
| |
|
|
|
